Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by Duster340on Sep 12, 2022 3:11pm
118 Views
Post# 34957457

Ate is in the wrong line of business

Ate is in the wrong line of business

Alex Jones Still Sells Supplements On Amazon Despite Bans From Other Platforms

 

Alex Jones addresses a pro-Trump crowd on Jan. 6, the day of the U.S. Capitol riot. Jones is widely known for his support of baseless and often bigoted conspiracy theories, and he has been banned from many tech platforms, though not Amazon.

Jon Cherry/Getty Images

The far-right conspiracy theorist Alex Jones has been banned from Facebook, Apple, YouTube, Instagram, Pinterest, Twitter, Spotify and even PayPal for violating those sites' policies against hate speech. But Jones continues to have a platform to sell expensive dietary supplements through one of the world's biggest online retailers: Amazon.

Just as Amazon provides massive third-party sellers — such as Starbucks, Coca-Cola or Apple — with their own online storefronts, Jones' Infowars Store has a home on the site, too. There, he sells products such as "Super Male Vitality" drops, "Lung Cleanse Plus Spray" and "Prostaguard" pills.

"Thank you for supporting the Infowar!" the storefront states above its listings, suggesting that Jones is not just selling supplements but providing a path for consumers to fund his extremist causes. Meanwhile, Amazon provides support to Jones and gets a percentage of all the sales — called a "referral fee" — as it does with all third-party sellers. For supplements priced over $10, the referral fee is 15%.

Neither Amazon nor Jones responded to NPR's requests for comment.


<< Previous
Bullboard Posts
Next >>